Neuroendocrine tumors of the pancreas: keys issues in dealing with heterogeneity.
We thank Modesto Varas et al. for their opportune comments with regard to the oncologic outcomes of our series of patients undergoing surgery for a pancreatic neuroendocrine tumor. We agree Varas et al. with respect to the increase in nonfunctional tumors (73%) and the figures of the incidental form of presentation (44%), which are in line with those from most series.